Information  X 
Enter a valid email address

EKF Diagnostics Hldg (EKF)

  Print      Mail a friend

Friday 12 October, 2018

EKF Diagnostics Hldg

Investor presentation

RNS Number : 8198D
EKF Diagnostics Holdings PLC
12 October 2018
 

EKF Diagnostics Holdings plc

("EKF" or the "Company") 

 

Investor presentation

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will host a briefing for all investors to provide details of the successful fundraising and proposed AIM admission of Renalytix AI plc ("RenalytixAI"), which was announced on the 11 October 2018.

 

The investor presentation will take place on Thursday 18 October 2018 at Côte Brasserie, 26 Ludgate Hill, London EC4M 7DR from 5.45 p.m. for a 6.00 p.m. start and will be followed by drinks. A presentation will be provided to shareholders and will be available on the company website at the start of the meeting: https://www.ekfdiagnostics.com/documents-reports.html

 

Regarding the Restricted Offer

The Restricted Offer referred to in the announcement on 11 October 2018 (the "Announcement") is only available to Qualifying EKF Shareholders, being persons who were recorded in the register of members of EKF at 8 p.m. on 10 October 2018 (the "Record Date") whose registered address is in the UK. Notifications, including an application form ("Application Form"), will be posted to Qualifying EKF Shareholders by RenalytixAI setting out further details of the Restricted Offer.

 

RenalytixAI is making the Restricted Offer, which is conditional, inter alia, on Admission, to all Qualifying EKF Shareholders to raise gross proceeds of up to £3.5 million.

 

Full details of the Restricted Offer can be found in the Print Proof Admission Document being made available online to Qualifying EKF Shareholders only via a weblink provided to them in the Application Form and correspondence from RenalytixAI and which is incorporated by reference into that correspondence. 

 

If you would like to register for the investor presentation, please contact Walbrook PR on 020 7933 8780 or email [email protected]

 

Terms used but not otherwise defined in this announcement shall have the meanings given to them in the Announcement.

 

Enquiries:

 

EKF Diagnostics Holdings plc 

 

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

 

 

 

Richard Evans, FD & COO

 

 


 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)

 

 


 

 

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About EKF Diagnostics Holdings plc www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAUAAKRWVARAAA

a d v e r t i s e m e n t